Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell Carcinoma

NCT06646588 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT06646588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06646588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell Carcinoma
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2024
Completion date
April 30, 2027
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neoplasms